Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corporation reports developments in healthcare technology for life sciences marketing, with updates centered on tools that connect pharmaceutical brands with healthcare professionals and patients. The company’s platform uses EHR-based access, omnichannel activation, the Dynamic Audience Activation Platform, and Micro-Neighborhood audiences to support HCP and direct-to-consumer engagement.
Recurring OptimizeRx news includes product and network launches, programmatic access to EHR advertising, privacy-safe identity resolution collaborations, quarterly and annual results, debt and share-repurchase actions, and board or leadership changes. Coverage also reflects the company’s focus on privacy-compliant audience targeting and campaign measurement across healthcare marketing channels.
OptimizeRx (OPRX) reported strong Q4 2024 results with revenue increasing 14% year-over-year to $32.3 million. Q4 gross profit grew 23% to $22.0 million with a 68% margin. Full-year 2024 revenue reached $92.1 million, up 29% from 2023.
The company doubled its DAAP deals from 24 in 2023 to 48 in 2024. Q4 non-GAAP net income was $5.5 million ($0.30 per diluted share), while Adjusted EBITDA increased 53% to $8.8 million. Full-year GAAP net loss was $(20.1) million.
Looking ahead, OptimizeRx provided 2025 guidance with expected revenue of at least $100 million and Adjusted EBITDA of at least $12 million. The company is transitioning DAAP customers to a subscription-based model for data services to improve margins and reduce business cyclicality.
OptimizeRx (Nasdaq: OPRX), a leading provider of healthcare technology solutions for life sciences companies, has confirmed receiving a notice of nominations from stockholder Whetstone Capital Advisors, . The notice indicates Whetstone's intention to nominate two candidates for election to the OptimizeRx Board of Directors at the company's 2025 Annual Meeting of Stockholders.
The OptimizeRx Board will review the nominations and provide their formal recommendation in the upcoming definitive proxy statement, which will be filed with the SEC and distributed to eligible voting stockholders. The company emphasized that no stockholder action is currently required, and the 2025 Annual Meeting date has not yet been scheduled.
OptimizeRx (Nasdaq: OPRX) has appointed Steve Silvestro as its new Chief Executive Officer, effective March 10, 2025. Silvestro, who has been with the company since 2019, brings over 20 years of experience in health technology and services.
Previously serving as Chief Commercial Officer, President, and interim CEO, Silvestro was unanimously selected by the independent Directors following a rigorous search process. During his tenure at OptimizeRx, he has been important in transforming the company from a single-solution digital marketing provider to an industry leader with omnichannel capabilities.
The new CEO's strategic priorities include:
- Focusing on operational excellence and customer satisfaction
- Expanding value proposition with pharmaceutical companies
- Increasing recurring revenue model
- Driving towards becoming a Rule of 40 company
- Creating new opportunities for profitable revenue growth
OptimizeRx (Nasdaq: OPRX), a leading provider of healthcare technology solutions for life sciences companies, has scheduled its Fourth Quarter and Full Year 2024 financial results conference call for March 12, 2025, at 8:30 a.m. ET. The company will release its financial results for the quarter ended December 31, 2024, via press release before the conference call. Management will host the call followed by a Q&A session. A replay will be accessible for 12 months through the Investors section of the OptimizeRx website.
OptimizeRx (Nasdaq: OPRX) announced that CEO William J. Febbo will depart the company effective December 31, 2024, with advisory services continuing through March 31, 2025. Stephen Silvestro, who has served as Chief Commercial Officer and President, has been appointed as interim CEO while the Board conducts a search for a permanent replacement.
During Febbo's nearly nine-year tenure, he transformed the company from a single point of care product to an omnichannel platform serving top pharmaceutical companies. The company reaffirmed its 2024 financial guidance, expecting results at the higher end of its revenue and adjusted EBITDA guidance range.
OptimizeRx Corp (Nasdaq: OPRX), a healthcare technology solutions provider, has announced its participation in two upcoming investor conferences in New York City. The company will attend the 13th Annual ROTH Technology Conference from November 19th-20th, 2024, at The Hard Rock Hotel, and Canaccord Genuity's 2024 CG MedTech, Diagnostics and Digital Health & Services Forum on November 21st, 2024, at The Westin NY Grand Central. Both events will feature one-on-one meeting formats with management.
OptimizeRx reported Q3 2024 financial results with revenue increasing 30% year-over-year to $21.3 million. Gross profit rose 37% to $13.4 million with a 63% margin. The company reported a GAAP net loss of $(9.1) million, while non-GAAP net income was $2.3 million. Adjusted EBITDA improved to $2.7 million from $0.9 million year-over-year. The company updated its 2024 guidance, expecting revenue between $88-92 million and Adjusted EBITDA of $8-10 million. Cash position strengthened to $16.1 million as of September 30, 2024.
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions, has scheduled its third quarter 2024 conference call for November 13, 2024, at 4:30 p.m. Eastern Time. The company will discuss financial results for the quarter ended September 30, 2024, which will be released before the call. Management will host the call followed by a Q&A session. The call will be accessible via toll-free and international numbers, with a webcast option available. A replay will be accessible for 12 months through the company's investor relations website.
OptimizeRx Corp. (Nasdaq: OPRX) has expanded its strategic relationship with a major pharma client, resulting in a multi-solution, multi-brand program with a total in-year commitment of over $10 million. This includes the previously mentioned $6 million DAAP contract, which is still undergoing internal review. The expansion demonstrates the value of OptimizeRx's solutions in driving stronger commercial performance through HCP and DTC marketing alignment.
Key highlights:
- Top 20 pharma clients now average $2.7 million in revenue per client
- Top 3 clients contribute $9.7 million in revenue
- Organic growth remains a key driver for the business
- The company is leveraging its omni-channel platform powered by AI-targeted reach
OptimizeRx Corp. (Nasdaq: OPRX) has launched Micro-Neighborhood® Targeting (MNT) on its Dynamic Audience Activation Platform (DAAP), enhancing Direct-to-Consumer (DTC) marketing for healthcare audiences. This AI-driven technology enables pharmaceutical brands to deliver synchronized DTC and healthcare professional (HCP) campaigns, predicting brand eligibility within the U.S. population.
Key features of DAAP include:
- AI-predicted brand eligibility signals for precise timing of point-of-care messaging
- Integration of real-world data through advanced machine learning models
- Personalized brand communications across various media channels
- Privacy-compliant connection of consumer and clinical data
The platform has demonstrated an average script lift of 25% in HCP audiences over the past three years, offering a more streamlined approach to reach specific patient and provider segments.